# US 2025/0051308 A1 · Clazosentan disodium salt, its preparation and pharmaceutical compositions comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0051308 A1
- Document ID: US20250051308A1
- Status: Published application
- Kind: A1
- Application number: 18/720,031
- Filed: 2022-12-16
- Published: 2025-02-13
- Earliest claimed: 2021-12-17
- Assignees: Idorsia Pharmaceuticals Ltd
- Applicants: Idorsia Pharmaceuticals Ltd
- Inventors: Iris AIGLSTORFER-HAAG; Thomas ISARNO
- Web page: https://patentgrep.com/patent/US20250051308A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to clazosentan disodium salt and a process for the preparation thereof.

## Claims

### Claim 1

A compound of Formula 6
characterized in that
said compound has a sodium content from 7.2% w/w to 7.7% w/w;
and/or
a test solution of 2.5% w/v of said compound in water is equally or less colored than any one of reference solutions Y5, BY5, GY5, or B5; as determined according to Chapter 2.2.2. of the European Pharmacopoeia 6.0; and/or
said compound is crystalline;
and/or
said compound is in a non-hydrated form;
and/or
said compound is in a non-solvated form;
and/or
said compound has an assay of at least 98% w/w, as determined by high-performance liquid chromatography; and/or
said compound comprises a total amount of impurities of not more than 2% w/w, as determined by high-performance liquid chromatography;
and/or
said compound comprises a total amount of residual solvents of less than 1% w/w, wherein the solvents are selected from a group consisting of ethanol, methanol, tetrahydrofuran, dimethylformamide, and ethylene glycol; as determined by gas chromatography.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein said compound is crystalline, wherein said crystalline compound is characterized by an X-ray powder diffractogram with at least four peaks having an angle of refraction 2θ selected from: 9.4°, 12.0°, 13.2°, 17.7°, 18.4°, 19.8°, 21.2°, 21.9°, and 24.9°.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein said compound is crystalline, wherein said crystalline compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 9.4°, 12.0°, and 21.9°.

### Claim 4 (depends on 1)

A compound according to claim 1, wherein said compound is crystalline, wherein said crystalline compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 9.4°, 12.0°, 18.4°, 21.2°, and 21.9°.

### Claim 5 (depends on 1)

A compound according to claim 1, wherein said compound is crystalline, wherein said crystalline compound is characterized by the presence of peaks in the X-ray powder diffractogram at the following angles of refraction 2θ: 9.4°, 12.0°, 13.2°, 17.7°, 18.4°, 19.8°, 21.2°, 21.9°, and 24.9°.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein said compound is crystalline, wherein said crystalline compound is characterized in that the X-ray powder diffractogram essentially shows the pattern as depicted in FIG. 1.

### Claim 7 (depends on 1)

A process for the preparation of the compound of Formula 6 according to claim 1, said process comprising the following steps
(e) reacting the compound of Formula 5 or a solvate thereof
with a sodium containing base, to give the compound of Formula 6
(f) purifying the compound of Formula 6 by
(f1) recrystallizing the compound of Formula 6 in water at pH≥7;
and
(f2) triturating the compound of Formula 6 in a solvent selected from methanol, ethanol, or a mixture thereof;
(g) drying the compound of Formula 6.

### Claim 8 (depends on 7)

A process according to claim 7, said process comprising the following steps
(a) reacting the compound of Formula 1
with 5-methyl-pyridine-2-sulfonamide or a salt thereof, under basic conditions, to give the compound of Formula 2 or a salt thereof
(b) reacting the compound of Formula 2 or a salt thereof with ethylene glycol in the presence of an alkali metal hydroxide, to give the compound of Formula 3 or a salt thereof
(c) reacting the compound of Formula 3 or a salt thereof with trimethylsilyl cyanide in the presence of a mono-, di-, or tri-C1-4-alkyl amine, to give the compound of Formula 4
(d) reacting the compound of Formula 4 with an alkali metal azide in the presence of ammonium chloride, to give the compound of Formula 5 or a solvate thereof
and (e), (f), and (g), each according to claim 7.

### Claim 9 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1, wherein said composition further comprises at least one pharmaceutically acceptable carrier.

### Claim 10 (depends on 9)

A pharmaceutical composition according to claim 9, said composition comprising
from 23.5 mg/ml to 26.5 mg/ml of the compound, wherein said concentration refers to the compound in its free acid form;
from 8.0 mg/mL to 12.0 mg/mL tris(hydroxymethyl)aminomethane;
from 0.08 mg/ml to 0.12 mg/mL disodium edetate;
from 2.0 mg/mL to 3.0 mg/mL sodium chloride; and
water;
wherein the pH value of said composition is from 7.0 to 9.0.

### Claim 11 (depends on 10)

A pharmaceutical composition according to claim 10, wherein said composition is equally or less colored than reference solution GY3, as determined according to Chapter 2.2.2. of the European Pharmacopoeia 6.0.

### Claim 12

(canceled)

### Claim 13 (depends on 1)

A method for the prevention of cerebral vasospasm, and vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage surgery/securing, wherein said method comprises administering to a subject in need thereof an effective amount of the compound according to claim 1.

### Claim 14 (depends on 1)

A method for the prevention of cerebral vasospasm, and vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage surgery, wherein said method comprises dissolving the compound according to claim 1 in an aqueous solution to form a pharmaceutical composition suitable for intravenous administration and administering to a subject in need thereof a said pharmaceutical composition as an intravenous continuous infusion at a dosage of 10 mg/h, wherein said dosage refers to the amount of the compound in its free acid form, wherein said administration starts after surgery of aneurysmal subarachnoid hemorrhage and continues for up to 15 days after aneurysmal rupture.

### Claim 15

(canceled)

### Claim 16 (depends on 2)

A pharmaceutical composition comprising the compound according to claim 2, wherein said composition further comprises at least one pharmaceutically acceptable carrier.

### Claim 17 (depends on 3)

A pharmaceutical composition comprising the compound according to claim 3, wherein said composition further comprises at least one pharmaceutically acceptable carrier.

### Claim 18 (depends on 4)

A pharmaceutical composition comprising the compound according to claim 4, wherein said composition further comprises at least one pharmaceutically acceptable carrier.

### Claim 19 (depends on 5)

A pharmaceutical composition comprising the compound according to claim 5, wherein said composition further comprises at least one pharmaceutically acceptable carrier.

### Claim 20 (depends on 6)

A pharmaceutical composition comprising the compound according to claim 6, wherein said composition further comprises at least one pharmaceutically acceptable carrier.

### Claim 21 (depends on 1)

A process for the preparation of a pharmaceutical composition comprising Formula 6
wherein said process comprises mixing the compound according to claim 1 with at least one pharmaceutically acceptable carrier.
